Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Bullboard Posts
Comment by mjn797979on Jul 24, 2020 4:56pm
41 Views
Post# 31316903

RE:RE:RE:RE:RE:RE:RE:Benedict ...

RE:RE:RE:RE:RE:RE:RE:Benedict ...I agree with what you just said Benedict.
If you have something good, you tell people.

In this case even more so, since the share price is significantly lower then the days following the acquisition where it briefly touched 8.75$.
There was enthusiasm because they finally did something with money.

Ok Covid hit but most of the market has rallied since.

As far as the buybacks go, I agree that if they can target another way to use that money, they should.
I doubt it though as they seem to have their hands full with this latest acquisition.
I would be very surprised they are also actively going after something else.

Anyways, I knew what I was getting into when I bought this.
Only thing I did not expect was the price of the stock to depreciate to 2014 levels after finally doing something with their cash reserves.
How long can the market go underevaluating this company? Or maybe it knows something we don't.

Bullboard Posts